161 related articles for article (PubMed ID: 19850775)
1. FDA approves pralatrexate for treatment of rare lymphoma.
Thompson CA
Am J Health Syst Pharm; 2009 Nov; 66(21):1890. PubMed ID: 19850775
[No Abstract] [Full Text] [Related]
2. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
[TBL] [Abstract][Full Text] [Related]
3. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.
Malik SM; Liu K; Qiang X; Sridhara R; Tang S; McGuinn WD; Verbois SL; Marathe A; Williams GM; Bullock J; Tornoe C; Lin SC; Ocheltree T; Vialpando M; Kacuba A; Justice R; Pazdur R
Clin Cancer Res; 2010 Oct; 16(20):4921-7. PubMed ID: 20739433
[TBL] [Abstract][Full Text] [Related]
4. Pralatrexate (Folotyn).
Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
[TBL] [Abstract][Full Text] [Related]
5. Hematology: relapsed and refractory PTCL--into the therapeutic abyss.
Foss F
Nat Rev Clin Oncol; 2011 Jun; 8(6):321-2. PubMed ID: 21468128
[No Abstract] [Full Text] [Related]
6. Pralatrexate - from bench to bedside.
Zain JM; Marchi E
Drugs Today (Barc); 2010 Feb; 46(2):91-9. PubMed ID: 20393637
[TBL] [Abstract][Full Text] [Related]
7. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
[TBL] [Abstract][Full Text] [Related]
8. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.
O'Connor OA; Amengual J; Colbourn D; Deng C; Sawas A
Leuk Lymphoma; 2017 Nov; 58(11):2548-2557. PubMed ID: 28738754
[TBL] [Abstract][Full Text] [Related]
9. Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma.
Ong SY; Phipps C; Kaur H; Tan L; Lee YS
Ann Acad Med Singap; 2019 Sep; 48(9):298-300. PubMed ID: 31737895
[No Abstract] [Full Text] [Related]
10. A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature.
Ma H; Bhagat G; O'Connor OA
Leuk Lymphoma; 2019 Dec; 60(13):3300-3303. PubMed ID: 31184235
[No Abstract] [Full Text] [Related]
11. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
Foss FM
Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
[TBL] [Abstract][Full Text] [Related]
12. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Jennifer C Z; Sara Mohamed J; Salma A; Francine F
Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
[TBL] [Abstract][Full Text] [Related]
13. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
[TBL] [Abstract][Full Text] [Related]
14. Pralatrexate (Folotyn) for peripheral T-cell lymphoma.
Med Lett Drugs Ther; 2010 Jul; 52(1342):55-6. PubMed ID: 20622807
[No Abstract] [Full Text] [Related]
15. Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate.
Sekiguchi Y; Wakabayashi M; Takizawa H; Iizuka H; Sakajiri S; Sugimoto K; Inano T; Fukuda Y; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Komatsu N; Noguchi M
J Clin Exp Hematop; 2020; 60(1):26-28. PubMed ID: 32224563
[No Abstract] [Full Text] [Related]
16. Pralatrexate, a new hope for aggressive T-cell lymphomas?
Rueda A; Casanova M; Quero C; Medina-Pérez A
Clin Transl Oncol; 2009 Apr; 11(4):215-20. PubMed ID: 19380298
[TBL] [Abstract][Full Text] [Related]
17. Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
Lee SS; Jung SH; Ahn JS; Kim YK; Cho MS; Jung SY; Lee JJ; Kim HJ; Yang DH
J Korean Med Sci; 2016 Jul; 31(7):1160-3. PubMed ID: 27366017
[TBL] [Abstract][Full Text] [Related]
18. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.
Foss FM; Parker TL; Girardi M; Li A
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e445-e447. PubMed ID: 30181105
[No Abstract] [Full Text] [Related]
19. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Molina JR
IDrugs; 2008 Jul; 11(7):508-21. PubMed ID: 18600598
[TBL] [Abstract][Full Text] [Related]
20. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
